## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.9% below STRENGTH zone (3.0-6.0%); PEG 1.97 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($199.64)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Cardinal Health (CAH) Repositions for Growth with Specialty and Services**
- Source: Insider Monkey | 20260103T001013 | Bullish | Relevance: 100%
- Cardinal Health (NYSE:CAH) has shown strong performance by shifting its focus to higher-margin specialty pharmaceuticals and managed services, leading to increased earnings growth and a favorable dividend payout ratio. The company recently raised its fiscal 2026 outlook, anticipating adjusted earnings per share between $9.65 and $9.85, reflecting robust first-quarter results and the upcoming acquisition of Solaris Health. While CAH is considered a strong investment, the article suggests that certain AI stocks may offer even greater upside potential.

**2. February 2026 Options Now Available For Cardinal Health (CAH)**
- Source: Nasdaq | 20251231T172922 | Somewhat-Bullish | Relevance: 100%
- New options contracts for Cardinal Health (CAH) expiring in February 2026 are now available. Stock Options Channel identified a put contract at a $200 strike and a call contract at a $210 strike, providing potential strategies for investors looking to buy at a discount or generate income through covered calls. The article details the potential returns and risks associated with these new options.

**3. Hennessy Advisors Inc. Sells 4,900 Shares of Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20260101T121905 | Bullish | Relevance: 100%
- Hennessy Advisors Inc. reduced its stake in Cardinal Health, Inc. by 5.3% in the third quarter, selling 4,900 shares and ending with 87,500 shares valued at $13.734 million. Cardinal Health exceeded Q3 expectations with EPS of $2.55 and revenue of $64.01 billion, prompting analysts to raise price targets and maintain a "Moderate Buy" rating with an average target of $209. The company also declared a quarterly dividend of $0.5107, representing an annualized dividend of $2.04 and a yield of 1.0%.

**4. Diversified Trust Co Decreases Stake in Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20260101T093423 | Bullish | Relevance: 100%
- Diversified Trust Co reduced its stake in Cardinal Health, Inc. (NYSE:CAH) by 42.5% in the third quarter, selling 5,827 shares and retaining 7,890 shares valued at $1.238 million. This institutional selling occurred despite Cardinal Health surpassing earnings expectations with an EPS of $2.55 and revenue of $64.01 billion, alongside setting strong FY2026 guidance. The company also announced a quarterly dividend and holds a "Moderate Buy" consensus rating from Wall Street analysts.

**5. Traders Purchase High Volume of Call Options on Cardinal Health (NYSE:CAH)**
- Source: MarketBeat | 20251231T213742 | Bullish | Relevance: 100%
- Traders have significantly increased their call option purchases on Cardinal Health (NYSE:CAH), with activity up 808% to 27,965 calls. This surge follows the company's recent earnings beat, raised FY2026 guidance, and substantial institutional buying interest, contributing to a "Moderate Buy" consensus among analysts with an average price target of $209.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $243 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.97 elevated, pricing in significant growth expectations. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $48.9B |
| Beta | 0.64 |
| 52W Range | $119.00 - $214.93 |
| Short Interest | 2.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.97 |
| Forward P/E | 18.6 |
| Current P/E | 20.9 |
| YoY Growth | 12.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 0.9% (minimal 5-day change). Below STRENGTH zone by 2.1pp (needs >3.0% for momentum thesis). MRS_5 at 0.3% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.93% (CS: 55) | Neutral |
| RSI_14 | 60.2 | Neutral |
| MACD Histogram | -0.06 | Bearish |
| vs SMA20 | 1.018x | Above |
| vs SMA50 | 1.038x | Above |
| vs SMA200 | 1.264x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $205.72
- **Stop Loss:** $199.64 (3.0% risk)
- **Target:** $211.80 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 236
- **Position Value:** $48,549.92
- **Portfolio %:** 48.55%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.3% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*